Orca Bio to Present Clinical Data on TREGZI™ and Pipeline at Hematologic Oncology Meeting
Orca Bio, a commercial-stage biotechnology company based in Menlo Park, California, has announced that three clinical data and study updates will be presented and published at the 14th Annual Meeting of the Society of Hematologic Oncology. The meeting is scheduled to take place from September 9-12 in Houston, Texas. The presentations will include new data on TREGZI™, Orca Bio's recently FDA-approved precision-engineered cell therapy for allogeneic transplant in adults with hematologic malignancies. Additionally, an encore presentation will cover Orca Bio’s investigational allogeneic T-cell immunotherapy, Orca-Q®. Nate Fernhoff, Ph.D., co-founder and chief executive officer of Orca Bio, emphasized the importance of this event for sharing information about TREGZI's profile with the hematology community and providing updates on the company's clinical development program. The presentations will detail infection events with TREGZI versus conventional allogeneic hematopoietic stem cell transplantation (alloHSCT)... 
